Pharma Companies Seek High Court Review Of Ruling Reversing FCA Suit Dismissal
WASHINGTON, D.C. — Pharmaceutical companies accused of violating the False Claims Act (FCA) by artificially inflating drug prices filed a petition for writ of certiorari in the U.S. Supreme Court, seeking...To view the full article, register now.
Already a subscriber? Click here to view full article